Clinicopathological factors, such as age, estrogen receptor (ER) and/or progesterone receptor (PR) status, nuclear grade, and tumor size, were believed to be associated with risk of local recurrence (LR) and progression to invasive cancer in DCIS patients [4, 5]. Here, ESR1 is linked to ductal breast carcinoma in situ.